Phase X ensures that lead optimization truly enhances drug safety and efficacy profiles in humans, not just in animal models. This strategy maximizes the chances that preclinical data will successfully translate during clinical development.
Clinical candidate selection based on human cell and tissue data, provides the best opportunity for successful clinical development and completely avoids the risks posed by species differences between animal models and human patient populations.
Access to human tissue samples from both healthy as well as diseased donors allows for the discovery of novel molecular targets. The high quality of samples procured employing Phase X technology, combined with proprietary laboratory equipment, enables the generation of highly reliable data gene expression profiling, proteomics, metabolomics and system biology parameters.
Early identification of human-relevant hit and lead compounds.